Search results
Federal Court Invalidates Dosing Patent Based On Clinical Trials Disclosure | JD Supra
JD Supra· 5 days agoAs an essential component of the drug development process, human clinical trials assist in determining whether a given drug will serve its intended...
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias...
FOX40 Sacramento· 2 days agoStarting from molecular design, the unique approach of α bias with β and γ attenuated were...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 5 days agoFlamingo Therapeutics Announces Poster Presentation at EACR 2024 Congress on FLM-7523 (FTX-001), a First-in-Class Inhibitor of the Long Non-Coding RNA MALAT1 PR Newswire LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, June 10, 2024 LEUVEN
New EHA data reveal how badly Gilead's $4.9B bet on CD47 imploded
FierceBiotech· 21 hours agoGilead Sciences' abandoned anti-CD47 drug magrolimab was not just ineffective, but could potentially...
100 Ways To Make Money Without a Job
GOBankingRates via Yahoo Finance· 3 days agoIf you want to make money outside of a 9-to-5 job, then you should take a look at these 100 ways to score some income without having a traditional job.
Eli Lilly Runs Up 49% With Expectations For Weight-Loss Sales To Triple
Investor's Business Daily· 3 days agoRevenue from Eli Lilly's weight-loss drug is expected to triple over the next five years to over $50...
Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy
FierceBiotech· 3 days agoAvidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to...
MDs' One-Word Summary of Long COVID Progress: 'Frustration'
Medscape· 4 days agoStuart Malcolm, MD, a primary care physician who practices in Oregon and northern California,...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 3 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy ...
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater...
Morningstar· 3 days agoAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced ...